Cytokinetics, Incorporated (CYTK)
NEUTRALFundamental
32
Price
$77.95
Market Cap
$10.70B
Part 1 · What the company is worth
Overview
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$68M
Trailing 12 months (through 6/30/2026)
Net Income
$-894M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$-535M
Total Equity
$-660M
Total Liabilities
$2.08B
Current Ratio
6.66
Interest Coverage
13.43
Debt/EBITDA
-
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$65.59
Current Price
$77.95
Margin of Safety
-18.8%
Fair Value Range
$42.64 - $88.55
Estimation Methods
Valuation Metrics
P/E Ratio
-
ROE
119.0%
P/B Ratio
-
P/FCF
-
Gross Margin
-
ROIC
-32.1%
Profitability Radar
Value Creation (Economic Moat)
ROIC
-32.1%
WACC
8.0%
ROIC − WACC
-40.1 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (6)
- Price CAGR 20.26%
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Revenue Growth 5Y 9.6%
- Analyst Consensus 89% Buy
Failed (11)
- EPS shows upward trend
- ROIC -32.1%
- Operating Margin -1046.1%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Overvalued)
- ROE -131.2%
- Earnings Surprise avg -12.0%
- Share Dilution 7.1%
- Net Margin Trend -1321.1% vs -707.2%
- Piotroski F-Score 2/9
Unavailable (10)
- Gross Margin NaN%
- P/FCF NaN
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Serious financial concerns
Earnings Quality
Low quality: investigate accounting
Share Dilution
Issuing new shares, diluting ownership
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Robert I. Blum | CEO, President & Director | 61 |
| Mr. Sung H. Lee | EVP & CFO | 55 |
| Mr. Jeffrey J. Hessekiel J.D. | Executive VP, Chief Legal & Administrative Officer | 56 |
| Dr. Fady Ibraham Malik FACC, M.D., Ph.D. | Executive Vice President of Research & Development | 61 |
| Mr. Andrew M. Callos | Executive VP & Chief Commercial Officer | 56 |
| Dr. James H. Sabry M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | 67 |
| Dr. James A. Spudich Ph.D. | Co-Founder & Member of Scientific Advisory Board | 83 |
| Mr. Jeff Lotz | Vice President of Sales & Operations | - |
| Ms. Holly Laughlin | VP of Accounting & Corporate Controller | - |
| Mr. Steven M. Cook J.D. | Senior Vice President of Global Supply Chain Operations & Technical Operations | 66 |
Audit Risk
5
Board Risk
3
Compensation Risk
8
Shareholder Rights Risk
7
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Latest News
Recent headlines for CYTK, sourced from Markets Gazette.
- 3/9/2026POSITIVECytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market
A significant insider transaction at Cytokinetics Inc. has been reported, with an executive exercising stock options valued at over $920,000. This occurs as the company's cardiac drug candidate progresses towards market entry. The exercise of options by an insider often signals confidence in the company's future prospects and the value of its stock. Coupled with the impending market launch of a key therapeutic, this event suggests positive momentum for Cytokinetics, potentially attracting further investor interest and supporting share price appreciation.
- 2/24/2026NEUTRALCytokinetics (CYTK) Q4 2025 Earnings Transcript
The financial community is keenly awaiting the Q4 2025 earnings transcript from Cytokinetics (CYTK). While specific details are not yet available, the analysis of such documents is crucial for investors looking to assess the biopharmaceutical company's operational performance and future prospects. Transcripts offer direct insights into management discussions regarding financial results, drug pipeline advancements, and growth strategies. Analysts will closely monitor any indications concerning key drugs like omecamtiv mecarbil or aficamten, as well as projections for the current fiscal year. The current lack of specific data suggests a cautious approach, but the release is a standard event providing transparency and a basis for informed decisions.
via Markets Gazette